Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000466492 | SCV000552968 | benign | Spastic paraplegia | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000519338 | SCV000619216 | uncertain significance | not provided | 2019-06-29 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV001271972 | SCV002026547 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2021-09-05 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV001271972 | SCV002548929 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2021-09-03 | criteria provided, single submitter | clinical testing | The c.1033C>T (p.Arg345Trp) variant identified in the SACS gene substitutes a well conserved Arginine for Tryptophan at amino acid 345/4580 (exon 8/10). This variant is found with low frequency in gnomAD(v3.1.1)(16 heterozygotes, 0 homozygotes; allele frequency: 1.05e-5) suggesting it is not a common benign variant in the populations represented in that database. In silico algorithms predict this variant to be Damaging (SIFT; score:0.001) and Pathogenic (REVEL;score:0.6349) to the function of the canonical transcript. This variant is reported as a Variant of Uncertain Significance in ClinVar (VarID:411689), and to our current knowledge has not been reported in affected individuals in the literature. The p.Arg345 residue is not within a mapped domain of SACS (UniProtKB:Q9NZJ4). Given the lack of compelling evidence for its pathogenicity, the c.1033C>T (p.Arg345Trp) variant identified in the SACS gene is reported as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004022883 | SCV004944903 | uncertain significance | Inborn genetic diseases | 2023-09-26 | criteria provided, single submitter | clinical testing | The c.1033C>T (p.R345W) alteration is located in exon 8 (coding exon 7) of the SACS gene. This alteration results from a C to T substitution at nucleotide position 1033, causing the arginine (R) at amino acid position 345 to be replaced by a tryptophan (W). Based on data from gnomAD, the T allele has an overall frequency of 0.006% (15/251392) total alleles studied. The highest observed frequency was 0.02% (6/30612) of South Asian alleles. This amino acid position is well conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001271972 | SCV001453566 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2020-09-16 | no assertion criteria provided | clinical testing |